Edwina J Wright1, Birgit Grund2, Kevin R Robertson3, Lucette Cysique4, Bruce J Brew5, Gary L Collins6, Mollie Poehlman-Roediger6, Michael J Vjecha7, Augusto César Penalva de Oliveira8, Barbara Standridge9, Cate Carey10, Anchalee Avihingsanon11, Eric Florence12, Jens D Lundgren13, Alejandro Arenas-Pinto14, Nicolas J Mueller15, Alan Winston16, Moses S Nsubuga17, Luxshimi Lal18, Richard W Price19. 1. Department of Infectious Diseases Alfred Health, Monash University, Burnet Institute, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia. 2. School of Statistics, University of Minnesota, Minneapolis, Minnesota. 3. Department of Neurology, University of North Carolina, North Carolina, USA. 4. Neurosciences Research Australia, St. Vincent's Hospital Sydney, Applied Medical Research Centre. 5. Neurosciences Program, Peter Duncan Neurosciences Unit, St Vincent's Centre for Applied Medical Research, University of New South Wales, Sydney, Australia. 6. Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota. 7. Institute for Clinical Research, Inc, Washington, DC, USA. 8. Instituto Emilio Ribas, Sao Paulo, Brazil. 9. Veterans Affairs Medical Center, Washington DC, USA. 10. Kirby Institute, University of New South Wales, Sydney, Australia. 11. HIV-NAT Thai Red Cross AIDS Research Centre and Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. 12. Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium. 13. CHIP, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Denmark. 14. MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, London, UK. 15. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zürich, Switzerland. 16. Division of Infectious Diseases, Department of Medicine, Imperial College London, London, UK. 17. People in Need Agency (PINA), Uganda. 18. Burnet Institute, Melbourne, Australia. 19. Department of Neurology, University of California San Francisco, San Francisco, California, USA.
Abstract
OBJECTIVE: To compare the effect of immediate versus deferred antiretroviral treatment (ART) on neuropsychological test performance in treatment-naive HIV-positive adults with more than 500 CD4 cells/μl. DESIGN: Randomized trial. METHODS: The START parent study randomized participants to commence immediate versus deferred ART until CD4 less than 350 cells/μl. The START Neurology substudy used eight neuropsychological tests, at baseline, months 4, 8, 12 and annually, to compare groups for changes in test performance. Test results were internally standardized to z-scores. The primary outcome was the average of the eight test z-scores (QNPZ-8). Mean changes in QNPZ-8 from baseline were compared by intent-to-treat using longitudinal mixed models. Changes from baseline to specific time points were compared using ANCOVA models. RESULTS: The 592 participants had a median age of 34 years; median baseline CD4 count was 629 cells/μl; the mean follow-up was 3.4 years. ART was used for 94 and 32% of accrued person-years in the immediate and deferred groups, respectively. There was no difference between the immediate and deferred ART groups in QNPZ-8 change through follow-up [-0.018 (95% CI -0.062 to 0.027, P = 0.44)], or at any visit. However, QNPZ-8 scores increased in both arms during the first year, by 0.22 and 0.24, respectively (P < 0.001 for increase from baseline). CONCLUSION: We observed substantial improvement in neurocognitive test performance during the first year in both study arms, underlining the importance of using a control group in studies assessing neurocognitive performance over time. Immediate ART neither benefitted nor harmed neurocognitive performance in individuals with CD4 cell counts above 500 cells/μl.
RCT Entities:
OBJECTIVE: To compare the effect of immediate versus deferred antiretroviral treatment (ART) on neuropsychological test performance in treatment-naive HIV-positive adults with more than 500 CD4 cells/μl. DESIGN: Randomized trial. METHODS: The START parent study randomized participants to commence immediate versus deferred ART until CD4 less than 350 cells/μl. The START Neurology substudy used eight neuropsychological tests, at baseline, months 4, 8, 12 and annually, to compare groups for changes in test performance. Test results were internally standardized to z-scores. The primary outcome was the average of the eight test z-scores (QNPZ-8). Mean changes in QNPZ-8 from baseline were compared by intent-to-treat using longitudinal mixed models. Changes from baseline to specific time points were compared using ANCOVA models. RESULTS: The 592 participantshad a median age of 34 years; median baseline CD4 count was 629 cells/μl; the mean follow-up was 3.4 years. ART was used for 94 and 32% of accrued person-years in the immediate and deferred groups, respectively. There was no difference between the immediate and deferred ART groups in QNPZ-8 change through follow-up [-0.018 (95% CI -0.062 to 0.027, P = 0.44)], or at any visit. However, QNPZ-8 scores increased in both arms during the first year, by 0.22 and 0.24, respectively (P < 0.001 for increase from baseline). CONCLUSION: We observed substantial improvement in neurocognitive test performance during the first year in both study arms, underlining the importance of using a control group in studies assessing neurocognitive performance over time. Immediate ART neither benefitted nor harmed neurocognitive performance in individuals with CD4 cell counts above 500 cells/μl.
Authors: Robert L Heilbronner; Jerry J Sweet; Deborah K Attix; Kevin R Krull; George K Henry; Robert P Hart Journal: Clin Neuropsychol Date: 2010-11 Impact factor: 3.535
Authors: Ronald J Ellis; Scott Letendre; Florin Vaida; Richard Haubrich; Robert K Heaton; Ned Sacktor; David B Clifford; Brookie M Best; Susanne May; Anya Umlauf; Mariana Cherner; Chelsea Sanders; Craig Ballard; David M Simpson; Cheryl Jay; J Allen McCutchan Journal: Clin Infect Dis Date: 2013-12-18 Impact factor: 9.079
Authors: Aylin Yilmaz; Kaj Blennow; Lars Hagberg; Staffan Nilsson; Richard W Price; Judith Schouten; Serena Spudich; Jonathan Underwood; Henrik Zetterberg; Magnus Gisslén Journal: Expert Rev Mol Diagn Date: 2017-06-14 Impact factor: 5.225
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: Lucette A Cysique; Donald Franklin; Ian Abramson; Ronald J Ellis; Scott Letendre; Ann Collier; David Clifford; Benjamin Gelman; Justin McArthur; Susan Morgello; David Simpson; J Allen McCutchan; Igor Grant; Robert K Heaton Journal: J Clin Exp Neuropsychol Date: 2011-03-07 Impact factor: 2.475
Authors: J C McArthur; D R Hoover; H Bacellar; E N Miller; B A Cohen; J T Becker; N M Graham; J H McArthur; O A Selnes; L P Jacobson Journal: Neurology Date: 1993-11 Impact factor: 9.910
Authors: L A Cysique; F Vaida; S Letendre; S Gibson; M Cherner; S P Woods; J A McCutchan; R K Heaton; R J Ellis Journal: Neurology Date: 2009-05-27 Impact factor: 9.910
Authors: James H Cole; Jonathan Underwood; Matthan W A Caan; Davide De Francesco; Rosan A van Zoest; Robert Leech; Ferdinand W N M Wit; Peter Portegies; Gert J Geurtsen; Ben A Schmand; Maarten F Schim van der Loeff; Claudio Franceschi; Caroline A Sabin; Charles B L M Majoie; Alan Winston; Peter Reiss; David J Sharp Journal: Neurology Date: 2017-03-03 Impact factor: 9.910
Authors: Birgit Grund; Edwina J Wright; Bruce J Brew; Richard W Price; Mollie P Roediger; Margaret P Bain; Jennifer F Hoy; Judith C Shlay; Michael J Vjecha; Kevin R Robertson Journal: J Neurovirol Date: 2013-08-14 Impact factor: 2.643
Authors: Miriam T Weber; Alan Finkelstein; Md Nasir Uddin; Elizabeth Asiago Reddy; Roberto C Arduino; Lu Wang; Madalina E Tivarus; Jianhui Zhong; Xing Qiu; Giovanni Schifitto Journal: Neurology Date: 2022-06-22 Impact factor: 11.800
Authors: Samuel R Schnittman; Amelia N Deitchman; Gabriele Beck-Engeser; HaeLee Ahn; Vanessa A York; Heather Hartig; Frederick M Hecht; Jeffrey N Martin; Steven G Deeks; Francesca T Aweeka; Peter W Hunt Journal: J Infect Dis Date: 2021-05-20 Impact factor: 7.759